Abera Bioscience AB — Investor Relations & Filings

Abera Bioscience AB is a biotechnology company developing next-generation mucosal vaccines using its proprietary, modular Outer Membrane Vesicle (OMV) platform. This technology enables the rapid design and cost-effective, scalable production of vaccines delivered primarily via nasal spray. The company's approach aims to induce strong and durable mucosal and systemic immunity against infectious diseases. Its development pipeline includes a serotype-independent pneumococcal vaccine candidate preparing for Phase 1 clinical trials and a nasal influenza vaccine in preclinical development. The platform is designed for global health applications, with potential for powder formulations to reduce cold-chain dependency and improve accessibility.